| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000084 | Mitotic s phase | Increases phenotype | PMID:33577917 |
| GO:0002718 | Regulation of cytokine production involved in immune response | Affects phenotype | PMID:9780043 |
| GO:0002923 | Regulation of humoral immune response mediated by circulating immunoglobulin | Affects phenotype | PMID:9780043 |
| GO:0005975 | Carbohydrate metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006000 | Fructose metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006163 | Purine nucleotide metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006213 | Pyrimidine nucleoside metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006220 | Pyrimidine nucleotide metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006518 | Peptide metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006520 | Amino acid metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006600 | Creatine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006631 | Fatty acid metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006693 | Prostaglandin metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:36529159 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:12760867 |
| GO:0008202 | Steroid metabolic process | Affects phenotype | PMID:36529159 |
| GO:0008203 | Cholesterol metabolic process | Affects phenotype | PMID:36529159 |
| GO:0008206 | Bile acid metabolic process | Affects phenotype | PMID:36529159 |
| GO:0008219 | Cell death | Increases phenotype | PMID:27099147 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:17210188; PMID:29112301; PMID:36529159; PMID:9722937 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:26385866; PMID:32112805; PMID:33577917 |
| GO:0009308 | Amine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:29112301 |
| GO:0019369 | Arachidonic acid metabolic process | Affects phenotype | PMID:36529159 |
| GO:0019530 | Taurine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0019752 | Carboxylic acid metabolic process | Affects phenotype | PMID:36529159 |
| GO:0019858 | Cytosine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0032729 | Positive regulation of type ii interferon production | Increases phenotype | PMID:10190717 |
| GO:0032743 | Positive regulation of interleukin-2 production | Increases phenotype | PMID:10190717 |
| GO:0032760 | Positive regulation of tumor necrosis factor production | Increases phenotype | PMID:10190717 |
| GO:0034969 | Histone arginine methylation | Decreases phenotype | PMID:33577917 |
| GO:0034971 | Histone h3-r17 methylation | Decreases phenotype | PMID:34919946 |
| GO:0039694 | Viral rna genome replication | Decreases phenotype | PMID:27303697 |
| GO:0042278 | Purine nucleoside metabolic process | Affects phenotype | PMID:36529159 |
| GO:0043985 | Histone h4-r3 methylation | Decreases phenotype | PMID:34919946 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:34919946; PMID:36529159 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Increases phenotype | PMID:33577917 |
| GO:0046100 | Hypoxanthine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0046102 | Inosine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0046108 | Uridine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0046449 | Creatinine metabolic process | Affects phenotype | PMID:36529159 |
| GO:0046483 | Heterocycle metabolic process | Affects phenotype | PMID:36529159 |
| GO:0046649 | Lymphocyte activation | Increases phenotype | PMID:17210188 |
| GO:0048598 | Embryonic morphogenesis | Decreases phenotype | PMID:26385866 |
| GO:0051892 | Negative regulation of cardioblast differentiation | Increases phenotype | PMID:32112805 |
| GO:0052838 | Thiazole metabolic process | Affects phenotype | PMID:36529159 |
| GO:0120252 | Hydrocarbon metabolic process | Affects phenotype | PMID:36529159 |
| GO:1901732 | Quercetin metabolic process | Affects phenotype | PMID:36529159 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:32112805 |
| GO:2000551 | Regulation of t-helper 2 cell cytokine production | Affects phenotype | PMID:9780043 |
| GO:2000554 | Regulation of t-helper 1 cell cytokine production | Affects phenotype | PMID:9780043 |
| GO:2000556 | Positive regulation of t-helper 1 cell cytokine production | Increases phenotype | PMID:10190717 |
| GO:2000726 | Negative regulation of cardiac muscle cell differentiation | Increases phenotype | PMID:32112805 |
| GO:2001022 | Positive regulation of response to dna damage stimulus | Increases phenotype | PMID:32112805 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.